NYSEAMERICAN:XTNT Xtant Medical - XTNT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xtant Medical Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.71 +0.03 (+3.65%) (As of 01/30/2023 03:12 PM ET) Add Compare Share Share Today's Range$0.68▼$0.7150-Day Range N/A52-Week Range$0.43▼$0.92Volume20,915 shsAverage Volume26,353 shsMarket Capitalization$77.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Xtant Medical (NYSEAMERICAN:XTNT) StockXtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.Read More Receive XTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address XTNT Stock News HeadlinesJanuary 9, 2023 | finance.yahoo.comXtant Medical Appoints Mark Schallenberger as Chief Operations OfficerNovember 21, 2022 | finance.yahoo.comXtant Medical Honors Donor Hero Asante Contreras on the Donate Life Rose Parade® FloatJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 9, 2022 | proactiveinvestors.comXtant Medical targets new opportunities for growth in robust demand environmentNovember 5, 2022 | seekingalpha.comXtant Medical Holdings, Inc. (XTNT) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finanznachrichten.deXtant Medical, Inc.: Xtant Medical Announces Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comXtant Medical Announces Third Quarter 2022 Financial ResultsOctober 27, 2022 | finance.yahoo.comXtant Medical to Issue Third Quarter 2022 Financial Results on November 3, 2022January 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." October 11, 2022 | finance.yahoo.comXtant Medical Announces Closing of Second Tranche of $9.75 Million Private InvestmentAugust 31, 2022 | finance.yahoo.comXtant Medical Announces Closing of First Tranche of $9.75 Million Private InvestmentAugust 24, 2022 | finance.yahoo.comXtant Medical Announces $9.75 Million Private InvestmentAugust 6, 2022 | seekingalpha.comXtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q2 2022 Results Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comXtant Medical Announces Second Quarter 2022 Financial ResultsJuly 28, 2022 | finance.yahoo.comXtant Medical to Issue Second Quarter 2022 Financial Results on August 4, 2022June 14, 2022 | seekingalpha.comXTNT Xtant Medical Holdings, Inc.May 8, 2022 | seekingalpha.comXtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | finance.yahoo.comXtant Medical Announces First Quarter 2022 Financial ResultsMay 2, 2022 | markets.businessinsider.comXtant Medical Confirms Scott Neils As New CFOMay 2, 2022 | seekingalpha.comXtant Medical names Scott Neils as CFOMay 2, 2022 | finance.yahoo.comXtant Medical Appoints Scott Neils as Chief Financial OfficerApril 28, 2022 | finance.yahoo.comXtant Medical to Issue First Quarter 2022 Financial Results on May 5, 2022March 15, 2022 | finance.yahoo.comXtant Medical to Present at the Canaccord Musculoskeletal Conference on March 22, 2022March 8, 2022 | seekingalpha.comXtant Medical GAAP EPS of -$0.03, revenue of $13.97MMarch 8, 2022 | finance.yahoo.comXtant Medical Announces Fourth Quarter and Full Year 2021 Financial ResultsMarch 1, 2022 | finance.yahoo.comXtant Medical to Issue Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022January 4, 2022 | finance.yahoo.comXtant Medical to Present at the H.C. Wainwright BioConnect Virtual ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address XTNT Company Calendar Last Earnings11/03/2022Today1/30/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:XTNT Previous SymbolAMEX:XTNT CUSIPN/A CIK1453593 Webxtantmedical.com Phone(406) 388-0480Fax406-388-1354Employees116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,850,000.00 Net Margins-15.11% Pretax Margin-15.19% Return on Equity-28.28% Return on Assets-15.81% Debt Debt-to-Equity Ratio0.33 Current Ratio3.97 Quick Ratio2.48 Sales & Book Value Annual Sales$55.26 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book1.97Miscellaneous Outstanding Shares108,660,000Free Float105,291,000Market Cap$77.15 million OptionableNot Optionable Beta0.58 Key ExecutivesSean E. BrownePresident, Chief Executive Officer & DirectorMark SchallenbergerChief Operating OfficerScott NeilsChief Financial OfficerKevin D. BrandtChief Commercial Officer & Senior Vice PresidentStephen C. SmithVP-Regulatory Affairs & Quality AssuranceKey CompetitorsCurisNASDAQ:CRISOrchard TherapeuticsNASDAQ:ORTXMiNK TherapeuticsNASDAQ:INKTaTyr PharmaNASDAQ:LIFEX4 PharmaceuticalsNASDAQ:XFORView All CompetitorsInsiders & InstitutionsScott C NeilsSold 8,673 sharesTotal: $5,290.53 ($0.61/share)Vanguard Group Inc.Bought 1,117,910 shares on 11/15/2022Ownership: 1.029%Renaissance Technologies LLCSold 43,690 shares on 11/14/2022Ownership: 0.577%Sean E BrowneSold 80,000 sharesTotal: $54,400.00 ($0.68/share)Stavros G VizirgianakisBought 2,264,861 shares on 10/7/2022Total: $1.09 M ($0.48/share)View All Insider TransactionsView All Institutional Transactions XTNT Stock - Frequently Asked Questions Are investors shorting Xtant Medical? Xtant Medical saw a decline in short interest during the month of December. As of December 30th, there was short interest totaling 313,100 shares, a decline of 35.3% from the December 15th total of 484,300 shares. Based on an average daily volume of 35,700 shares, the short-interest ratio is presently 8.8 days. Approximately 1.3% of the shares of the company are sold short. View Xtant Medical's Short Interest. When is Xtant Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our XTNT earnings forecast. How were Xtant Medical's earnings last quarter? Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) released its earnings results on Thursday, November, 3rd. The medical device company reported ($0.03) EPS for the quarter. The medical device company earned $14.46 million during the quarter. Xtant Medical had a negative net margin of 15.11% and a negative trailing twelve-month return on equity of 28.28%. When did Xtant Medical's stock split? Xtant Medical's stock reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Xtant Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH), LadRx (CYTR), Protalix BioTherapeutics (PLX), Heat Biologics (HTBX), Neovasc (NVCN), Rexahn Pharmaceuticals (REXN), Biopharmx (BPMX), Adamis Pharmaceuticals (ADMP), Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP). What is Xtant Medical's stock symbol? Xtant Medical trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XTNT." How do I buy shares of Xtant Medical? Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xtant Medical's stock price today? One share of XTNT stock can currently be purchased for approximately $0.69. How much money does Xtant Medical make? Xtant Medical (NYSEAMERICAN:XTNT) has a market capitalization of $74.98 million and generates $55.26 million in revenue each year. The medical device company earns $-4,850,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. How many employees does Xtant Medical have? The company employs 116 workers across the globe. How can I contact Xtant Medical? Xtant Medical's mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The official website for the company is xtantmedical.com. The medical device company can be reached via phone at (406) 388-0480, via email at investorrelations@xtantmedical.com, or via fax at 406-388-1354. This page (NYSEAMERICAN:XTNT) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.